Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors

Angel Chao, Tzu Hao Wang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

The successful development of the proteasome inhibitor bortezomib as an anticancer drug has improved survival in patients with multiple myeloma. With the emergence of the newly US Food and Drug Administration-approved proteasome inhibitor carfilzomib, ongoing trials are investigating this compound and other proteasome inhibitors either alone or in combination with other chemotherapy drugs. However, in solid tumors, the efficacy of proteasome inhibitors has not lived up to expectations. Results regarding the potential clinical efficacy of bortezomib combined with other agents in the treatment of solid tumors are eagerly awaited. Recent identification of the molecular mechanisms (involving apoptosis and autophagy) by which bortezomib and cisplatin can overcome chemotherapy resistance and sensitize tumor cells to anticancer therapy can provide insights into the development of novel therapeutic strategies for patients with solid malignancies.

Original languageEnglish
Pages (from-to)3-8
Number of pages6
JournalTaiwanese Journal of Obstetrics and Gynecology
Volume55
Issue number1
DOIs
StatePublished - 01 02 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016.

Keywords

  • Apoptosis
  • Autophagy
  • Bortezomib
  • Proteasome inhibitors
  • Solid tumors

Fingerprint

Dive into the research topics of 'Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors'. Together they form a unique fingerprint.

Cite this